Vincenzo Cerundolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7200390/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The P5-type ATPase ATP13A1 modulates major histocompatibility complex I-related protein 1 (MR1)-mediated antigen presentation. Journal of Biological Chemistry, 2022, 298, 101542.	3.4	7
2	Decitabine increases neoantigen and cancer testis antigen expression to enhance T-cell–mediated toxicity against glioblastoma. Neuro-Oncology, 2022, 24, 2093-2106.	1.2	18
3	Deletion of the deISGylating enzyme USP18 enhances tumour cell antigenicity and radiosensitivity. British Journal of Cancer, 2021, 124, 817-830.	6.4	31
4	Hepcidin-Mediated Hypoferremia Disrupts Immune Responses to Vaccination and Infection. Med, 2021, 2, 164-179.e12.	4.4	53
5	PLGA Nanoparticles Co-encapsulating NY-ESO-1 Peptides and IMM60 Induce Robust CD8 and CD4 T Cell and B Cell Responses. Frontiers in Immunology, 2021, 12, 641703.	4.8	21
6	HLA-E–restricted, Gag-specific CD8 ⁺ T cells can suppress HIV-1 infection, offering vaccine opportunities. Science Immunology, 2021, 6, .	11.9	35
7	Chromatin accessibility governs the differential response of cancer and TÂcells to arginine starvation. Cell Reports, 2021, 35, 109101.	6.4	20
8	Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1 ₁₅₇₋₁₆₅ tumor-specific peptide. , 2021, 9, e002544.		9
9	The Chemical Synthesis, Stability, and Activity of MAIT Cell Prodrug Agonists That Access MR1 in Recycling Endosomes. ACS Chemical Biology, 2020, 15, 437-445.	3.4	24
10	Self-Maintaining CD103+ Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses. Cancer Immunology Research, 2020, 8, 203-216.	3.4	27
11	Cell identity and nucleo-mitochondrial genetic context modulate OXPHOS performance and determine somatic heteroplasmy dynamics. Science Advances, 2020, 6, eaba5345.	10.3	31
12	The Immune Modulating Properties of Mucosal-Associated Invariant T Cells. Frontiers in Immunology, 2020, 11, 1556.	4.8	29
13	Re-evaluation of human BDCA-2+ DC during acute sterile skin inflammation. Journal of Experimental Medicine, 2020, 217, .	8.5	29
14	Structural and functional characterization of C0021158, a high-affinity monoclonal antibody that inhibits Arginase 2 function via a novel non-competitive mechanism of action. MAbs, 2020, 12, 1801230.	5.2	2
15	Ligand-dependent downregulation of MR1 cell surface expression. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 10465-10475.	7.1	43
16	Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma. , 2020, 8, e000410.		21
17	Nanovaccine administration route is critical to obtain pertinent iNKt cell help for robust anti-tumor T and B cell responses. Oncolmmunology, 2020, 9, 1738813.	4.6	37
18	Extensive sequence and structural evolution of Arginase 2 inhibitory antibodies enabled by an unbiased approach to affinity maturation. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 16949-16960.	7.1	10

#	Article	IF	CITATIONS
19	Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model. British Journal of Cancer, 2020, 123, 1089-1100.	6.4	51
20	The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells. Cancer Cell, 2020, 37, 226-242.e7.	16.8	117
21	Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells. Cancer Immunology Research, 2020, 8, 685-697.	3.4	6
22	Interactions Between MAIT Cells and Dendritic Cells. Methods in Molecular Biology, 2020, 2098, 125-139.	0.9	0
23	Sterile activation of invariant natural killer T cells by ER-stressed antigen-presenting cells. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 23671-23681.	7.1	21
24	A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer. Frontiers in Oncology, 2019, 9, 1066.	2.8	43
25	Capturing the antigen landscape: HLA-E, CD1 and MR1. Current Opinion in Immunology, 2019, 59, 121-129.	5.5	17
26	Enriched HLA-E and CD94/NKG2A Interaction Limits Antitumor CD8+ Tumor-Infiltrating T Lymphocyte Responses. Cancer Immunology Research, 2019, 7, 1293-1306.	3.4	46
27	NOD2 and TLR2 Signal via TBK1 and PI31 to Direct Cross-Presentation and CD8 T Cell Responses. Frontiers in Immunology, 2019, 10, 958.	4.8	31
28	Behaviour and neuropathology in mice injected with human contactin-associated protein 2 antibodies. Brain, 2019, 142, 2000-2012.	7.6	35
29	Cytoskeletal Control of Antigen-Dependent T Cell Activation. Cell Reports, 2019, 26, 3369-3379.e5.	6.4	68
30	Discovery of <i>Salmonella</i> trehalose phospholipids reveals functional convergence with mycobacteria. Journal of Experimental Medicine, 2019, 216, 757-771.	8.5	20
31	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of nonâ€muscleâ€invasive disease. BJU International, 2019, 123, 947-958.	2.5	9
32	The Impact of Vaccination and Prior Exposure on Stool Shedding of Salmonella Typhi and Salmonella Paratyphi in 6 Controlled Human Infection Studies. Clinical Infectious Diseases, 2019, 68, 1265-1273.	5.8	26
33	A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC) Journal of Clinical Oncology, 2019, 37, 406-406.	1.6	8
34	Generation of a double binary transgenic zebrafish model to study myeloid gene regulation in response to oncogene activation in melanocytes. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	14
35	Somatic <i>POLE</i> exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response. Journal of Pathology, 2018, 245, 283-296.	4.5	71
36	MAIT cell clonal expansion and TCR repertoire shaping in human volunteers challenged with Salmonella ParatyphiÂA. Nature Communications, 2018, 9, 253.	12.8	107

#	Article	IF	CITATIONS
37	NKG2A, a New Kid on the Immune Checkpoint Block. Cell, 2018, 175, 1720-1722.	28.9	83
38	Diverse Streptococcus pneumoniae Strains Drive a Mucosal-Associated Invariant T-Cell Response Through Major Histocompatibility Complex class l–Related Molecule–Dependent and Cytokine-Driven Pathways. Journal of Infectious Diseases, 2018, 217, 988-999.	4.0	59
39	Clonal analysis of Salmonella-specific effector T cells reveals serovar-specific and cross-reactive T cell responses. Nature Immunology, 2018, 19, 742-754.	14.5	27
40	Dendritic cells enter lymph vessels by hyaluronan-mediated docking to the endothelial receptor LYVE-1. Nature Immunology, 2017, 18, 762-770.	14.5	147
41	Modulation of cancer-specific immune responses by amino acid degrading enzymes. Immunotherapy, 2017, 9, 83-97.	2.0	78
42	Activation of Human Mucosal-Associated Invariant T Cells Induces CD40L-Dependent Maturation of Monocyte-Derived and Primary Dendritic Cells. Journal of Immunology, 2017, 199, 2631-2638.	0.8	96
43	Snapin promotes <scp>HIV</scp> â€l transmission from dendritic cells by dampening <scp>TLR</scp> 8 signaling. EMBO Journal, 2017, 36, 2998-3011.	7.8	15
44	Active nuclear transcriptome analysis reveals inflammasome-dependent mechanism for early neutrophil response to Mycobacterium marinum. Scientific Reports, 2017, 7, 6505.	3.3	26
45	Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy. Frontiers in Immunology, 2017, 8, 1829.	4.8	49
46	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight, 2017, 2, e91868.	5.0	59
47	Psoriatic T cells recognize neolipid antigens generated by mast cell phospholipase delivered by exosomes and presented by CD1a. Journal of Experimental Medicine, 2016, 213, 2399-2412.	8.5	194
48	Nutritional Stress Induced by Tryptophan-Degrading Enzymes Results in ATF4-Dependent Reprogramming of the Amino Acid Transporter Profile in Tumor Cells. Cancer Research, 2016, 76, 6193-6204.	0.9	45
49	Elevated and crossâ€responsive CD1aâ€reactive T cells in bee and wasp venom allergic individuals. European Journal of Immunology, 2016, 46, 242-252.	2.9	51
50	Nonâ€glycosidic compounds can stimulate both human and mouse <i>i</i> NKT cells. European Journal of Immunology, 2016, 46, 1224-1234.	2.9	14
51	B-cell repertoire dynamics after sequential hepatitis B vaccination and evidence for cross-reactive B-cell activation. Genome Medicine, 2016, 8, 68.	8.2	64
52	The actin cytoskeleton modulates the activation of iNKT cells by segregating CD1d nanoclusters on antigen-presenting cells. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E772-81.	7.1	29
53	Systems biology of immunity to MF59-adjuvanted versus nonadjuvanted trivalent seasonal influenza vaccines in early childhood. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1853-1858.	7.1	176
54	Filaggrin inhibits generation of CD1a neolipid antigens by house dust mite–derived phospholipase. Science Translational Medicine, 2016, 8, 325ra18.	12.4	77

#	Article	IF	CITATIONS
55	Co-delivery of PLGA encapsulated invariant NKT cell agonist with antigenic protein induce strong T cell-mediated antitumor immune responses. OncoImmunology, 2016, 5, e1068493.	4.6	68
56	Human autoreactive T cells recognize CD1b and phospholipids. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 380-385.	7.1	85
57	T lymphocytes need less than 3 min to discriminate between peptide MHCs with similar TCRâ€binding parameters. European Journal of Immunology, 2015, 45, 1635-1642.	2.9	12
58	NKT-dependent B-cell activation in Gaucher disease. Blood, 2015, 125, 1200-1202.	1.4	3
59	MR1-Restricted Mucosal-Associated Invariant T Cells and Their Activation during Infectious Diseases. Frontiers in Immunology, 2015, 6, 303.	4.8	66
60	Regulation of Lipid Specific and Vitamin Specific Non-MHC Restricted T Cells by Antigen Presenting Cells and Their Therapeutic Potentials. Frontiers in Immunology, 2015, 6, 388.	4.8	15
61	In-Depth Assessment of Within-Individual and Inter-Individual Variation in the B Cell Receptor Repertoire. Frontiers in Immunology, 2015, 6, 531.	4.8	92
62	The Processed Amino-Terminal Fragment of Human TLR7 Acts as a Chaperone To Direct Human TLR7 into Endosomes. Journal of Immunology, 2015, 194, 5417-5425.	0.8	15
63	Analysis of B Cell Repertoire Dynamics Following Hepatitis B Vaccination in Humans, and Enrichment of Vaccine-specific Antibody Sequences. EBioMedicine, 2015, 2, 2070-2079.	6.1	92
64	Bee venom processes human skin lipids for presentation by CD1a. Journal of Experimental Medicine, 2015, 212, 149-163.	8.5	98
65	BCR repertoire sequencing: different patterns of Bâ€cell activation after two Meningococcal vaccines. Immunology and Cell Biology, 2015, 93, 885-895.	2.3	83
66	The Regulatory Role of Invariant NKT Cells in Tumor Immunity. Cancer Immunology Research, 2015, 3, 425-435.	3.4	122
67	CD1d-dependent endogenous and exogenous lipid antigen presentation. Current Opinion in Immunology, 2015, 34, 116-125.	5.5	30
68	<scp>NYâ€ESO</scp> â€l specific antibody and cellular responses in melanoma patients primed with <scp>NYâ€ESO</scp> â€l protein in <scp>ISCOMATRIX</scp> and boosted with recombinant <scp>NYâ€ESO</scp> â€l fowlpox virus. International Journal of Cancer, 2015, 136, E590-601.	5.1	46
69	Autophagy is a critical regulator of memory CD8+ T cell formation. ELife, 2014, 3, .	6.0	276
70	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	1.8	395
71	High Frequency of Cytolytic 21-Hydroxylase–Specific CD8+ T Cells in Autoimmune Addison's Disease Patients. Journal of Immunology, 2014, 193, 2118-2126.	0.8	38
72	Essential role for autophagy during invariant NKT cell development. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5678-87.	7.1	95

#	Article	IF	CITATIONS
73	Biology of CD1- and MR1-Restricted T Cells. Annual Review of Immunology, 2014, 32, 323-366.	21.8	233
74	Combinatorial HLA-peptide bead libraries for high throughput identification of CD8+ T cell specificity. Journal of Immunological Methods, 2014, 403, 72-78.	1.4	8
75	Cutting Edge: Endoplasmic Reticulum Stress Licenses Macrophages To Produce Mature IL-1β in Response to TLR4 Stimulation through a Caspase-8– and TRIF-Dependent Pathway. Journal of Immunology, 2014, 192, 2029-2033.	0.8	149
76	Randomized, double-blind phase II trial of NY-ESO-1 ISCOMATRIX vaccine and ISCOMATRIX adjuvant alone in patients with resected stage IIc, III, or IV malignant melanoma Journal of Clinical Oncology, 2014, 32, 9050-9050.	1.6	4
77	Design, Synthesis, and Functional Activity of Labeled CD1d Glycolipid Agonists. Bioconjugate Chemistry, 2013, 24, 586-594.	3.6	13
78	Saposins modulate human invariant Natural Killer T cells self-reactivity and facilitate lipid exchange with CD1d molecules during antigen presentation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4753-61.	7.1	37
79	Cord Factor and Peptidoglycan Recapitulate the Th17-Promoting Adjuvant Activity of Mycobacteria through Mincle/CARD9 Signaling and the Inflammasome. Journal of Immunology, 2013, 190, 5722-5730.	0.8	112
80	DOCK8 is critical for the survival and function of NKT cells. Blood, 2013, 122, 2052-2061.	1.4	68
81	The location of splenic NKT cells favours their rapid activation by blood-borne antigen. EMBO Journal, 2012, 31, 2378-2390.	7.8	81
82	Invariant NKT Cell-Based Vaccine Strategies. , 2012, , 39-53.		2
83	Interaction Between Invariant NKT Cells and Myeloid-derived Suppressor Cells in Cancer Patients. Journal of Immunotherapy, 2012, 35, 449-459.	2.4	32
84	Globosides but Not Isoglobosides Can Impact the Development of Invariant NKT Cells and Their Interaction with Dendritic Cells. Journal of Immunology, 2012, 189, 3007-3017.	0.8	38
85	Amide Analogues of CD1d Agonists Modulate <i>i</i> NKT-Cell-Mediated Cytokine Production. ACS Chemical Biology, 2012, 7, 847-855.	3.4	24
86	Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses. Nature Immunology, 2012, 13, 35-43.	14.5	249
87	Kinetics and Mechanics of Two-Dimensional Interactions between T Cell Receptors and Different Activating Ligands. Biophysical Journal, 2012, 102, 248-257.	0.5	68
88	Invariant natural killer <scp>T</scp> cells are not affected by lysosomal storage in patients with <scp>N</scp> iemannâ€ <scp>P</scp> ick disease type <scp>C</scp> . European Journal of Immunology, 2012, 42, 1886-1892.	2.9	14
89	Towards multivalent CD1d ligands: synthesis and biological activity of homodimeric α-galactosyl ceramide analogues. Carbohydrate Research, 2012, 356, 152-162.	2.3	25
90	Reply to "Failure to detect production of IL-10 by activated human neutrophils". Nature Immunology, 2011, 12, 1018-1020.	14.5	22

#	Article	IF	CITATIONS
91	Antigen Potency and Maximal Efficacy Reveal a Mechanism of Efficient T Cell Activation. Science Signaling, 2011, 4, ra39.	3.6	71
92	Synthesis of truncated analogues of the iNKT cell agonist, α-galactosyl ceramide (KRN7000), and their biological evaluation. Bioorganic and Medicinal Chemistry, 2011, 19, 221-228.	3.0	8
93	Centriole polarisation to the immunological synapse directs secretion from cytolytic cells of both the innate and adaptive immune systems. BMC Biology, 2011, 9, 45.	3.8	60
94	Binding Strength and Dynamics of Invariant Natural Killer Cell T Cell Receptor/CD1d-Glycosphingolipid Interaction on Living Cells by Single Molecule Force Spectroscopy. Journal of Biological Chemistry, 2011, 286, 15973-15979.	3.4	20
95	Discovery of deoxyceramides and diacylglycerols as CD1b scaffold lipids among diverse groove-blocking lipids of the human CD1 system. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 19335-19340.	7.1	69
96	Diverse Endogenous Antigens for Mouse NKT Cells: Self-Antigens That Are Not Glycosphingolipids. Journal of Immunology, 2011, 186, 1348-1360.	0.8	54
97	Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time. Immunity, 2010, 32, 163-174.	14.3	214
98	Synthetic iNKT cell-agonists as vaccine adjuvants—finding the balance. Current Opinion in Immunology, 2010, 22, 417-424.	5.5	32
99	Recent advances in processing and presentation of CD1 bound lipid antigens. Current Opinion in Immunology, 2010, 22, 81-88.	5.5	50
100	CD169+ macrophages present lipid antigens to mediate early activation of iNKT cells in lymph nodes. Nature Immunology, 2010, 11, 303-312.	14.5	186
101	Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid A. Nature Immunology, 2010, 11, 1039-1046.	14.5	269
102	Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. Journal of Clinical Investigation, 2010, 120, 2889-2899.	8.2	71
103	Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells. Journal of Experimental Medicine, 2010, 207, 1261-1271.	8.5	613
104	Ca2+ Release from the Endoplasmic Reticulum of NY-ESO-1–Specific T Cells Is Modulated by the Affinity of TCR and by the Use of the CD8 Coreceptor. Journal of Immunology, 2010, 184, 1829-1839.	0.8	36
105	The role of invariant NKT cells at the interface of innate and adaptive immunity. Seminars in Immunology, 2010, 22, 59-60.	5.6	20
106	A Single-Chain H-2Db Molecule Presenting an Influenza Virus Nucleoprotein Epitope Shows Enhanced Ability at Stimulating CD8+ T Cell Responses In Vivo. Journal of Immunology, 2009, 182, 4565-4571.	0.8	16
107	Linking Inflammation to Natural Killer T Cell Activation. PLoS Biology, 2009, 7, e1000226.	5.6	17
108	Nonglycosidic Agonists of Invariant NKT Cells for Use as Vaccine Adjuvants. ChemMedChem, 2009, 4, 171-175.	3.2	22

#	Article	IF	CITATIONS
109	T Cell Receptor CDR2Î ² and CDR3Î ² Loops Collaborate Functionally to Shape the iNKT Cell Repertoire. Immunity, 2009, 31, 60-71.	14.3	90
110	Harnessing invariant NKT cells in vaccination strategies. Nature Reviews Immunology, 2009, 9, 28-38.	22.7	313
111	Synthesis and biological activity of α-galactosyl ceramide KRN7000 and galactosyl (α1→2) galactosyl ceramide. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 4288-4291.	2.2	33
112	Rational development of high-affinity T-cell receptor-like antibodies. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5784-5788.	7.1	109
113	Phage displayâ€derived recombinant antibodies with TCRâ€like specificity against αâ€galactosylceramide and its analogues in complex with human CD1d molecules. European Journal of Immunology, 2008, 38, 829-840.	2.9	15
114	CD1d presentation of glycolipids. Immunology and Cell Biology, 2008, 86, 588-597.	2.3	21
115	Structural and Functional Aspects of Lipid Binding by CD1 Molecules. Annual Review of Cell and Developmental Biology, 2008, 24, 369-395.	9.4	48
116	B cell receptor-mediated uptake of CD1d-restricted antigen augments antibody responses by recruiting invariant NKT cell help <i>in vivo</i> . Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8345-8350.	7.1	178
117	Cutting Edge: Nonglycosidic CD1d Lipid Ligands Activate Human and Murine Invariant NKT Cells. Journal of Immunology, 2008, 180, 6452-6456.	0.8	76
118	Invariant NKT cells reduce the immunosuppressive activity of influenza A virus–induced myeloid-derived suppressor cells in mice and humans. Journal of Clinical Investigation, 2008, 118, 4036-4048.	8.2	299
119	Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5977-5982.	7.1	198
120	Modulation of CD103 Expression on Human Colon Carcinoma-Specific CTL. Journal of Immunology, 2007, 178, 2908-2915.	0.8	45
121	Increasing the Survival of Dendritic Cells In Vivo Does Not Replace the Requirement for CD4+ T Cell Help during Primary CD8+ T Cell Responses. Journal of Immunology, 2007, 179, 5738-5747.	0.8	12
122	Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20490-20495.	7.1	173
123	Dendritic Cell Function Can Be Modulated through Cooperative Actions of TLR Ligands and Invariant NKT Cells. Journal of Immunology, 2007, 178, 2721-2729.	0.8	82
124	Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5971-5976.	7.1	145
125	Early acquisition of cytolytic function and transcriptional changes in a primary CD8+ T-cell response in vivo. Blood, 2007, 109, 1086-1094.	1.4	18
126	Structures of an MHC Class I Molecule from B21 Chickens Illustrate Promiscuous Peptide Binding. Immunity, 2007, 27, 885-899.	14.3	161

#	Article	IF	CITATIONS
127	A closer look at CD1d molecules: new horizons in studying NKT cells. Trends in Immunology, 2007, 28, 455-462.	6.8	22
128	The length of lipids bound to human CD1d molecules modulates the affinity of NKT cell TCR and the threshold of NKT cell activation. Journal of Experimental Medicine, 2007, 204, 1131-1144.	8.5	206
129	MHC-peptide-specific antibodies reveal inefficient presentation of an HLA-A*0201-restricted, Melan-A-derived peptide after active intracellular processing. European Journal of Immunology, 2007, 37, 2008-2017.	2.9	13
130	Enhanced immunogenicity of CTL antigens through mutation of the CD8 binding MHC class I invariant region. European Journal of Immunology, 2007, 37, 1323-1333.	2.9	60
131	T cell receptors get back to basics. Nature Immunology, 2007, 8, 1033-1035.	14.5	3
132	Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients. Cancer Immunity, 2007, 7, 7.	3.2	107
133	Description of HLA class I- and CD8-deficient patients: Insights into the function of cytotoxic T lymphocytes and NK cells in host defense. Seminars in Immunology, 2006, 18, 330-336.	5.6	42
134	Histone deacetylase inhibitors increase virus gene expression but decrease CD8+ cell antiviral function in HTLV-1 infection. Blood, 2006, 108, 3801-3807.	1.4	35
135	Regulation of hematopoiesis in vitro and in vivo by invariant NKT cells. Blood, 2006, 107, 3138-3144.	1.4	33
136	Characterization of Siglec-H as a novel endocytic receptor expressed on murine plasmacytoid dendritic cell precursors. Blood, 2006, 107, 3600-3608.	1.4	231
137	Expression of MHC Class I–Related Chain B (MICB) Molecules on Renal Transplant Biopsies. Transplantation, 2006, 81, 1196-1203.	1.0	51
138	HIV-1 down-regulates the expression of CD1d via Nef. European Journal of Immunology, 2006, 36, 278-286.	2.9	116
139	B and CTL responses to the ALK protein in patients with ALK-positive ALCL. International Journal of Cancer, 2006, 118, 688-695.	5.1	58
140	Structure and binding kinetics of three different human CD1d–α-galactosylceramide–specific T cell receptors. Journal of Experimental Medicine, 2006, 203, 699-710.	8.5	85
141	Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. Journal of Experimental Medicine, 2006, 203, 2293-2303.	8.5	127
142	Quantifying and Imaging NY-ESO-1/LAGE-1-Derived Epitopes on Tumor Cells Using High Affinity T Cell Receptors. Journal of Immunology, 2006, 176, 7308-7316.	0.8	93
143	Role of Immunoproteasomes in Cross-Presentation. Journal of Immunology, 2006, 177, 983-990.	0.8	74
144	The crystal structure of human CD1d with and without α-galactosylceramide. Nature Immunology, 2005, 6, 819-826.	14.5	363

#	Article	IF	CITATIONS
145	Viral Immunity: Cross-Priming with the Help of TLR3. Current Biology, 2005, 15, R336-R339.	3.9	29
146	Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. European Journal of Immunology, 2005, 35, 1681-1691.	2.9	528
147	Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. International Journal of Cancer, 2005, 113, 259-266.	5.1	89
148	Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients. International Journal of Cancer, 2005, 115, 450-455.	5.1	20
149	CD8+ T Cell Epitope-Flanking Mutations Disrupt Proteasomal Processing of HIV-1 Nef. Journal of Immunology, 2005, 175, 4618-4626.	0.8	63
150	Immunodominance of Poxviral-Specific CTL in a Human Trial of Recombinant-Modified Vaccinia Ankara. Journal of Immunology, 2005, 175, 8431-8437.	0.8	93
151	BCL6b mediates the enhanced magnitude of the secondary response of memory CD8+ T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 7418-7425.	7.1	76
152	Structural and kinetic basis for heightened immunogenicity of T cell vaccines. Journal of Experimental Medicine, 2005, 201, 1243-1255.	8.5	248
153	Regulation of Hematopoiesis In Vitro and In Vivo by Invariant NKT Cells Blood, 2005, 106, 2277-2277.	1.4	0
154	Impact of Alpha Interferon and Ribavirin on the Function of Maturing Dendritic Cells. Antimicrobial Agents and Chemotherapy, 2004, 48, 3382-3389.	3.2	57
155	CpG-matured Murine Plasmacytoid Dendritic Cells Are Capable of In Vivo Priming of Functional CD8 T Cell Responses to Endogenous but Not Exogenous Antigens. Journal of Experimental Medicine, 2004, 199, 567-579.	8.5	171
156	The Crystal Structure of Human CD1b with a Bound Bacterial Glycolipid. Journal of Immunology, 2004, 172, 2382-2388.	0.8	137
157	Intravenous Injection of a Lentiviral Vector Encoding NY-ESO-1 Induces an Effective CTL Response. Journal of Immunology, 2004, 172, 1582-1587.	0.8	106
158	Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection. PLoS Biology, 2004, 2, e20.	5.6	399
159	Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy. Journal of Clinical Investigation, 2004, 114, 1800-1811.	8.2	150
160	Dendritic cells: a journey from laboratory to clinic. Nature Immunology, 2004, 5, 7-10.	14.5	194
161	Gene therapy meets vaccine development. Trends in Biotechnology, 2004, 22, 623-626.	9.3	26
162	The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. Journal of Immunological Methods, 2004, 285, 25-40.	1.4	156

#	Article	IF	CITATIONS
163	Biological function of the soluble CEACAM1 protein and implications in TAP2-deficient patients. European Journal of Immunology, 2004, 34, 2138-2148.	2.9	32
164	Lack of dendritic cell maturation by the plant toxin ricin. European Journal of Immunology, 2004, 34, 2149-2157.	2.9	5
165	The mechanisms controlling NK cell autoreactivity in TAP2-deficient patients. Blood, 2004, 103, 1770-1778.	1.4	62
166	Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy. Journal of Clinical Investigation, 2004, 114, 1800-1811.	8.2	77
167	Plasmacytoid dendritic cells prime IFNâ€Î³â€secreting melanomaâ€specific CD8 lymphocytes and are found in primary melanoma lesions. European Journal of Immunology, 2003, 33, 1052-1062.	2.9	184
168	The influence of macrophage inflammatory protein-1alpha on protective immunity mediated by antiviral cytotoxic T cells. Immunology, 2003, 109, 68-75.	4.4	24
169	Immunopolarization of CD4+ and CD8+ T Cells to Type-1–Like is Associated with Melanocyte Loss in Human Vitiligo. Laboratory Investigation, 2003, 83, 683-695.	3.7	212
170	Frequency and Phenotype of Circulating Vα24/Vβ11 Double-Positive Natural Killer T Cells during Hepatitis C Virus Infection. Journal of Virology, 2003, 77, 2251-2257.	3.4	101
171	Identification of a TAP-Independent, Immunoproteasome-Dependent CD8 ⁺ T-Cell Epitope in Epstein-Barr Virus Latent Membrane Protein 2. Journal of Virology, 2003, 77, 2757-2761.	3.4	48
172	Anti-CD8 Antibodies Can Inhibit or Enhance Peptide-MHC Class I (pMHCI) Multimer Binding: This Is Paralleled by Their Effects on CTL Activation and Occurs in the Absence of an Interaction between pMHCI and CD8 on the Cell Surface. Journal of Immunology, 2003, 171, 6650-6660.	0.8	51
173	Generation of CD1 tetramers as a tool to monitor glycolipid–specific T cells. Philosophical Transactions of the Royal Society B: Biological Sciences, 2003, 358, 875-877.	4.0	12
174	Lytic versus stimulatory synapse in cytotoxic T lymphocyte/target cell interaction: Manifestation of a dual activation threshold. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14145-14150.	7.1	190
175	High Avidity Antigen-Specific CTL Identified by CD8-Independent Tetramer Staining. Journal of Immunology, 2003, 171, 5116-5123.	0.8	85
176	NKT Cells Enhance CD4+ and CD8+ T Cell Responses to Soluble Antigen In Vivo through Direct Interaction with Dendritic Cells. Journal of Immunology, 2003, 171, 5140-5147.	0.8	445
177	Efficient priming of antigen-specific cytotoxic T lymphocytes by human cord blood dendritic cells. International Immunology, 2003, 15, 1265-1273.	4.0	42
178	Mature CD8+ T lymphocyte response to viral infection during fetal life. Journal of Clinical Investigation, 2003, 111, 1747-1755.	8.2	140
179	Mature CD8+ T lymphocyte response to viral infection during fetal life. Journal of Clinical Investigation, 2003, 111, 1747-1755.	8.2	206
180	Short Communication: Differential Processing of HLA A2-Restricted HIV Type 1 Cytotoxic T Lymphocyte Epitopes. Viral Immunology, 2002, 15, 193-196.	1.3	5

#	Article	IF	CITATIONS
181	Exogenous Peptides Delivered by Ricin Require Processing by Signal Peptidase for Transporter Associated with Antigen Processing-Independent MHC Class I-Restricted Presentation. Journal of Immunology, 2002, 169, 99-107.	0.8	23
182	Vα24-JαQ-Independent, CD1d-Restricted Recognition of α-Galactosylceramide by Human CD4+ and CD8αβ+ T Lymphocytes. Journal of Immunology, 2002, 168, 5514-5520.	0.8	142
183	Competition Between CTL Narrows the Immune Response Induced by Prime-Boost Vaccination Protocols. Journal of Immunology, 2002, 168, 4391-4398.	0.8	145
184	Immunotherapy of colorectal cancer. British Medical Bulletin, 2002, 64, 181-200.	6.9	11
185	Novel CD8+ T Cell Antagonists Based on β2-Microglobulin. Journal of Biological Chemistry, 2002, 277, 20840-20846.	3.4	14
186	Fas ligand breaks tolerance to self-antigens and induces tumor immunity mediated by antibodies. Cancer Cell, 2002, 2, 315-322.	16.8	29
187	The use of HLA class I tetramers to design a vaccination strategy for melanoma patients. Immunological Reviews, 2002, 188, 155-163.	6.0	23
188	Structure of human CD1b with bound ligands at 2.3 Ã, a maze for alkyl chains. Nature Immunology, 2002, 3, 721-726.	14.5	234
189	Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Medicine, 2002, 8, 379-385.	30.7	1,432
190	Tracking T cells with tetramers: new tales from new tools. Nature Reviews Immunology, 2002, 2, 263-272.	22.7	163
191	A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using α3 Domain Mutants of MHC Class I/Peptide Complex. Immunity, 2001, 14, 591-602.	14.3	70
192	Immunotherapy of melanoma. Immunology, 2001, 104, 1-7.	4.4	17
193	Apoptotic cells overexpress vinculin and induce vinculin-specific cytotoxic T-cell cross-priming. Nature Medicine, 2001, 7, 807-813.	30.7	88
194	Mature Dendritic Cells Prime Functionally Superior Melan-A-Specific CD8+ Lymphocytes as Compared with Nonprofessional APC. Journal of Immunology, 2001, 167, 1188-1197.	0.8	64
195	Human T-Cell Leukemia Virus Type 1 Tax Protein Binds to Assembled Nuclear Proteasomes and Enhances Their Proteolytic Activity. Journal of Virology, 2001, 75, 11106-11115.	3.4	28
196	Antigen Processing Defects in Cervical Carcinomas Limit the Presentation of a CTL Epitope from Human Papillomavirus 16 E6. Journal of Immunology, 2001, 167, 5420-5428.	0.8	101
197	Effects of Retroviral Protease Inhibitors on Proteasome Function and Processing of HIV-Derived MHC Class I-Restricted Cytotoxic T Lymphocyte Epitopes. AIDS Research and Human Retroviruses, 2001, 17, 1063-1066.	1.1	12
198	Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generatedin vitro from CD34+ hematopoietic progenitor cells. International Journal of Cancer, 2000, 86, 385-392.	5.1	298

#	Article	IF	CITATIONS
199	Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells. European Journal of Immunology, 2000, 30, 705-708.	2.9	89
200	Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 4760-4765.	7.1	343
201	Tetramer-Guided Analysis of TCR β-Chain Usage Reveals a Large Repertoire of Melan-A-Specific CD8+ T Cells in Melanoma Patients. Journal of Immunology, 2000, 165, 533-538.	0.8	84
202	A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response. Journal of Immunology, 2000, 165, 6644-6652.	0.8	128
203	Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells. Journal of Immunology, 2000, 165, 3492-3496.	0.8	200
204	Induction of Potent Antitumor CTL Responses by Recombinant Vaccinia Encoding a Melan-A Peptide Analogue. Journal of Immunology, 2000, 164, 1125-1131.	0.8	75
205	RANTES activates antigen-specific cytotoxic T lymphocytes in a mitogen-like manner through cell surface aggregation. International Immunology, 2000, 12, 1173-1182.	4.0	68
206	Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL. Journal of Immunology, 2000, 165, 948-955.	0.8	161
207	Surface Expression of HLA-E, an Inhibitor of Natural Killer Cells, Enhanced by Human Cytomegalovirus gpUL40. Science, 2000, 287, 1031-1033.	12.6	554
208	Use of major histocompatibility complex class I tetramers to monitor tumor-specific cytotoxic T lymphocyte response in melanoma patients. Cancer Chemotherapy and Pharmacology, 2000, 46, S83-S85.	2.3	7
209	Dendritic cell maturation is induced by mycoplasma infection but not by necrotic cells. , 2000, 30, 705.		4
210	In Vivo Expression of Natural Killer Cell Inhibitory Receptors by Human Melanoma–Specific Cytolytic T Lymphocytes. Journal of Experimental Medicine, 1999, 190, 775-782.	8.5	179
211	An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions, Journal of Experimental Medicine, 1999, 190, 651-668.	8.5	186
212	Optimal activation of tumor-reactive T cells by selected antigenic peptide analogues. International Immunology, 1999, 11, 1971-1980.	4.0	49
213	High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals. Journal of Experimental Medicine, 1999, 190, 705-716.	8.5	447
214	Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyte–defined Peptide Derived from the Tumor Antigen MAGE-3. Journal of Experimental Medicine, 1999, 189, 895-906.	8.5	116
215	Developmental Regulation of Lck Targeting to the CD8 Coreceptor Controls Signaling in Naive and Memory T Cells. Journal of Experimental Medicine, 1999, 189, 1521-1530.	8.5	138
216	Tumour immunology: T cells work together to fight cancer. Current Biology, 1999, 9, R695-R697.	3.9	11

#	Article	IF	CITATIONS
217	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. European Journal of Immunology, 1999, 29, 1990-1999.	2.9	111
218	Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes. European Journal of Immunology, 1999, 29, 2213-2222.	2.9	27
219	Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet, The, 1999, 354, 1598-1603.	13.7	131
220	Exploiting retrograde transport of Shiga-like toxin 1 for the delivery of exogenous antigens into the MHC class I presentation pathway. FEBS Letters, 1999, 453, 95-99.	2.8	34
221	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. , 1999, 29, 1990.		1
222	CD28-negative cytolytic effector T cells frequently express NK receptors and are present at variable proportions in circulating lymphocytes from healthy donors and melanoma patients. European Journal of Immunology, 1999, 29, 1990-1999.	2.9	7
223	Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells. Journal of Clinical Investigation, 1999, 104, 173-180.	8.2	409
224	Differential processing of influenza nucleoprotein in human and mouse cells. European Journal of Immunology, 1998, 28, 625-635.	2.9	25
225	Independent contributions of HLA epitopes and killer inhibitory receptor expression to the functional alloreactive specificity of natural killer cells. Human Immunology, 1998, 59, 700-712.	2.4	15
226	Fast Association Rates Suggest a Conformational Change in the MHC Class I Molecule H-2Dbupon Peptide Binding. Biochemistry, 1998, 37, 3001-3012.	2.5	67
227	Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA. Science, 1998, 279, 2103-2106.	12.6	1,340
228	Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes. Journal of Experimental Medicine, 1998, 188, 1641-1650.	8.5	475
229	High Frequency of Skin-homing Melanocyte-specific Cytotoxic T Lymphocytes in Autoimmune Vitiligo. Journal of Experimental Medicine, 1998, 188, 1203-1208.	8.5	408
230	A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. Immunology Letters, 1997, 57, 183-187.	2.5	43
231	The proteasome-specific inhibitor lactacystin blocks presentation of cytotoxic T lymphocyte epitopes in human and murine cells. European Journal of Immunology, 1997, 27, 336-341.	2.9	122
232	Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport. European Journal of Immunology, 1995, 25, 554-562.	2.9	123
233	Antigen Processing and Presentation the Role of the Endoplasmic Reticulum. Sub-Cellular Biochemistry, 1993, 21, 209-228.	2.4	1
234	Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer. Nature, 1992, 355, 644-646.	27.8	341

#	Article	IF	CITATIONS
235	Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases. Cancer Immunology, Immunotherapy, 1992, 35, 27-32.	4.2	6
236	Structural requirements for the peptide-induced conformational change of free major histocompatibility complex class I heavy chains. European Journal of Immunology, 1992, 22, 2085-2091.	2.9	46
237	Short peptides assist the folding of free class I heavy chains in solution. European Journal of Immunology, 1992, 22, 3121-3125.	2.9	19
238	Peptide-induced conformational change of the class I heavy chain. Nature, 1991, 351, 402-406.	27.8	229
239	The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules. European Journal of Immunology, 1991, 21, 2069-2075.	2.9	186
240	Naturally processed peptides. Nature, 1990, 348, 195-196.	27.8	29
241	Functional activityin vivo of effector T cell populations III. Protection against Moloney murine sarcoma virus (M-MSV)-induced tumors in T cell deficient mice by the adoptive transfer of a M-MSV-specific cytolytic T lymphocyte clope. Furopean Journal of Immunology, 1987, 17, 173-178	2.9	14